SCHEMBL3680966

SCHEMBL3680966

CCCCCCCCCCCC(=O)c1c(C(=O)O)n(CCOc2ccc(CC(=O)O)cc2)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 8/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207598 0.90 PLA2G2A (0.71) PLA2G2A
SCHEMBL7212268 0.87 PLA2G2A (0.57) PLA2G2A
SCHEMBL7207563 0.83 PLA2G2A (0.66) PLA2G2A
SCHEMBL3683619 0.83 PLA2G2A (0.59) PLA2G2A
SCHEMBL9264175 0.82 PLA2G2A (0.78) PLA2G2A
SCHEMBL9263596 0.82 PLA2G2A (0.78) PLA2G2A
SCHEMBL9267156 0.82 PLA2G2A (0.78) PLA2G2A
SCHEMBL9268492 0.80 PLA2G2A (0.64) PLA2G2A
SCHEMBL9270260 0.79 PLA2G2A (0.74) PLA2G2A
SCHEMBL7208318 0.78 PLA2G2A (0.55) PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0923546-B1 ACYLPYRROLDICARBOXYLIC ACIDS AND ACYLINDOLDICARBOXYLIC ACIDS AND THEIR DERIVATIVES AND INHIBITORS OF THE CYTOSOLIC PHOSPHOLIPASE A2 MERCKLE GMBH (DE) 2003-11-26 EP claimed
US-6310217-B1 ANTIINFLAMMATORY AND ANALGESIC AGENTS MERCKLE GMBH (DE) 2001-10-30 US claimed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 US disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 US disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 US disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 EP disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 EP disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 WO disclosed
EP-0923546-B1 ACYLPYRROLDICARBOXYLIC ACIDS AND ACYLINDOLDICARBOXYLIC ACIDS AND THEIR DERIVATIVES AND INHIBITORS OF THE CYTOSOLIC PHOSPHOLIPASE A2 MERCKLE GMBH (DE) 2003-11-26 EP disclosed
US-6310217-B1 ANTIINFLAMMATORY AND ANALGESIC AGENTS MERCKLE GMBH (DE) 2001-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 PLA2G2A 596/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 PLA2G2A 596/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 PLA2G2A 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.